Skip to content Skip to sidebar Skip to footer

GrayMatters Health Awarded €2.5M in Funding from European Innovation Council

HAIFA, Israel – September 7, 2022 – GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental disorders, has been awarded a €2.5 million grant from the European Innovation Council (EIC) to accelerate the development of Prism for PTSD, a non-invasive digital therapy, to be used as an adjunct to standard of care (SOC) treatments…

Read More

GrayMatters Health Closes $10M Round A Funding and Partnership in Japan

Investment Led by Otsuka Medical Devices HAIFA, Israel, Jan. 11, 2022 /PRNewswire/ -- GrayMatters Health (GMH) developer of digital self-neuromodulation therapeutics for mental disorders, announced today the successful closing of its $10 million Series A financing round. Otsuka Medical Devices Co., Ltd. (OMD) was the lead investor in this round. In addition to its investment, OMD obtained certain rights with regard…

Read More